Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.
Key Data Updates in Multiple Myeloma from ASH 2023
Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.
Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.
Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.
Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
3
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
4
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
5